Progress on the launch of domestic generic cabozantinib drugs

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor, mainly used to treat a variety of malignant tumors such as advanced liver cancer and renal cell carcinoma (RCC). The original version of the drug is produced by Pfizer in the United States and has been approved in multiple countries. However, the current price of imported original cabozantinib is relatively high, causing many patients to face a certain financial burden. Therefore, there is a large demand for cabozantinib generics in the domestic market, especially if patients hope to reduce the cost of treatment through medical insurance reimbursement.

However, as of now, the research and development of domestic generic cabozantinib drugs has not been completed. Although Chinese pharmaceutical companies are actively developing related generic drugs, the launch of domestic generic drugs has been relatively slow because the original drug of cabozantinib is under patent protection. According to current drug regulatory policies and market conditions, it may take some time for domestic generic cabozantinib drugs to enter the market. Nonetheless, once generic drugs are on the market, they are expected to provide more affordable treatment options for Chinese patients, especially in terms of price, to compete with imported original drugs and reduce the financial burden on patients.

At present, some generic drug companies have carried out research and development of generic cabozantinib drugs in China and obtained regulatory approval through relevant clinical trials. However, due to factors such as pharmaceutical companies' R&D cycles, clinical trial results, and patent licensing, there is still uncertainty about the specific time for domestic generic drugs to be launched.

Although imported cabozantinib has not yet been launched in China, and domestic generic drugs are still in the research and development stage, with the continuous optimization of China’s drug regulatory policies and the gradual development of the generic drug industry, domestic generic cabozantinib drugs are expected to enter the market in the near future and help more patients in need of treatment.

Reference:https://en.wikipedia.org/wiki/Cabozantinib